Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

Epigenetic modifying enzymes such as histone deacetylases (HDACs), p300, and PRMT1 are recruited by AML1/ETO, the pathogenic protein for t(8;21) acute myeloid leukemia (AML), providing a strong molecular rationale for targeting these enzymes to treat this disease. Although early phase clinical asses...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bots, Michael, Verbrugge, Inge, Martin, Benjamin P., Salmon, Jessica M., Ghisi, Margherita, Baker, Adele, Stanley, Kym, Shortt, Jake, Ossenkoppele, Gert J., Zuber, Johannes, Rappaport, Amy R., Atadja, Peter, Lowe, Scott W., Johnstone, Ricky W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3938147/
https://ncbi.nlm.nih.gov/pubmed/24415537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-03-488114
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados